This case-control study compares cerebrospinal fluid (CSF) amyloid and tau biomarkers for Alzheimer disease in African American and white individuals with normal cognition and with mild cognitive impairment. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.